Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Version bumped from v3.0.1 to v3.0.2; the 'Back to Top' element has been removed.
    Difference
    0.1%
    Check dated 2025-09-13T17:38:50.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-06T15:23:39.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of cabozantinib. The revision number has also been updated to v3.0.0.
    Difference
    2%
    Check dated 2025-08-30T12:06:35.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T04:51:40.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11.
    Difference
    0.1%
    Check dated 2025-08-09T00:17:49.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.7%
    Check dated 2025-08-01T19:40:00.000Z thumbnail image

Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.